A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Clinical trial NCT02957019 · TERMINATED
Trial details
- NCT number
- NCT02957019
- Sponsor
- Philogen S.p.A.
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2013-07-31
- Primary completion
- 2023-09-01
- Enrollment
- 6
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.